Avidity Biosciences, Inc.(RNA)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Avidity Biosciences, Inc. (RNA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RNA at 25.2/100 on a 32-signal composite quality model, placing it at rank #2,670 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Avidity Biosciences, Inc. reports quarterly revenue of $3.0M, net income of $-20.2M, free cash flow of $-4.0M. Top institutional holders of RNA by reported 13-F value include Sessa Capital IM, L.P., PRICE T ROWE ASSOCIATES, BlackRock, based on the most recent SEC filings. RNA trades on the Nasdaq exchange and files with the SEC under CIK 1599901. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Avidity Biosciences, Inc. directly from SEC EDGAR.
AI Quality Score
25.2/100
AI Rank
#2,670
Revenue
$3.0M
Net Income
$-20.2M
Free Cash Flow
$-4.0M
RNA key financials by period
Avidity Biosciences, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$18.8M
$-684.6M
—
FY 2024
10-K
$10.9M
$-322.3M
—
FY 2023
10-K
$9.6M
$-212.2M
—
FY 2022
10-K
$9.2M
$-174.0M
—
FY 2021
10-K
$9.3M
$-118.0M
—
FY 2020
10-K
$6.8M
$-44.4M
—
Institutions holding RNA
Institutional investors reporting a position in Avidity Biosciences, Inc. on SEC Form 13F.
